Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Meeting Results for: September 23, 2009

Drug Name Review Type Committee Recommendation Prior Approval Status � Final Determination
Besivance New Drug Initial Review Require Prior Approval Prior Approval Required
Nascobal New Drug Initial Review Require Prior Approval Prior Approval Required
Santyl Ointment New Drug Initial Review Require Prior Approval Prior Approval Required
Toviaz New Drug Initial Review Require Prior Approval Prior Approval Required
Momexin New Drug Initial Review Require Prior Approval Prior Approval Required
Nucynta New Drug Initial Review Require Prior Approval Prior Approval Required
Bromfed DM New Drug Initial Review Require Prior Approval Prior Approval Required
Invega Sustenna New Drug Initial Review Require Prior Approval Prior Approval Required
Savella New Drug Initial Review Require Prior Approval Prior Approval Required
Multaq New Drug Initial Review Require Prior Approval Prior Approval Required
Saprhis New Drug Initial Review Require Prior Approval Prior Approval Required
Adcirca New Drug Initial Review Require Prior Approval Prior Approval Required
Onglyza New Drug Initial Review Require Prior Approval Prior Approval Required
Ulesfia New Drug Initial Review Require Prior Approval Prior Approval Required
Moxatag New Drug Appeal Removed from Agenda Prior Approval Required
PegIntron PDL Appeal Require Prior Approval Prior Approval Required
Advair PDL Appeal Remove Prior Approval Requirement Prior Approval Requirement Removed